In contrast to MPNs, where the specific JAK2 inhibitors sparing other kinases are discussed as the best treatment option [146], AML patients seem to benefit more from multikinase inhibitors, which, in addition to JAK-STAT, target another pathway(s). Here, SOAT1 is linked to acute myeloid leukemia.